var data={"title":"Amphotericin B cholesteryl sulfate complex (United States: not available): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amphotericin B cholesteryl sulfate complex (United States: not available): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5634?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-drug-information\" class=\"drug drug_general\">see &quot;Amphotericin B cholesteryl sulfate complex (United States: not available): Drug information&quot;</a> and <a href=\"topic.htm?path=amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amphotericin B cholesteryl sulfate complex (United States: not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134753\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Amphotec [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998129\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Parenteral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45360845\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Amphotec has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet, Amphotec, AmBisome) and conventional amphotericin B for injection.</b> Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> In neonates, lipid formulations of amphotericin have poorer penetration into the central nervous system, kidneys, urinary tract, and eyes than conventional amphotericin and are not preferred in most cases (IDSA [Pappas 2016]; <i>Red Book</i> [AAP 2015]; Turkova 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis</b>\n      <b>, invasive:</b> Limited data available: IV: 3 to 5 mg/kg/dose once daily; treatment should continue for at least 2 weeks after the first negative blood culture and signs and symptoms have resolved (IDSA [Pappas 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998155\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-drug-information\" class=\"drug drug_general\">see &quot;Amphotericin B cholesteryl sulfate complex (United States: not available): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Amphotec has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet, Amphotec, AmBisome) and conventional amphotericin B for injection.</b> Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> Premedication for patients who experience fever, chills, hypotension, nausea, or other nonanaphylactic infusion-related immediate reactions may be given 30 to 60 minutes prior to drug administration: NSAIDs (with or without diphenhydramine) <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone may be given (Paterson 2008); if patient experiences rigors during infusion, meperidine may be administered. The manufacturer&rsquo;s labeling advises a test dose be administered immediately preceding the first dose when a new course of treatment occurs. A small amount of drug (eg, 10 mL of final preparation containing between 1.6 and 8.3 mg of drug) should be infused over 15 to 30 minutes and patient should be carefully observed for the next 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Aspergillosis</i>, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Invasive: Infants, Children, and Adolescents: IV: Usual dose range: 3 to 4 mg/kg/dose once daily; doses as high as 7.5 mg/kg/dose have been described in open label studies (Sandler 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocarditis: Children and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, treatment: </b>Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Invasive: IV: 3 to 5 mg/kg/dose once daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocarditis: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015]; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Esophageal (HIV-exposed/-positive): Adolescents: IV: 3 to 4 mg/kg/dose once daily for 14 to 21 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coccidiodomycosis, disseminated (non-CNS) or diffuse pulmonary disease: </b>HIV-exposed/-infected:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: IV: 5 mg/kg/dose once daily until clinical improvement; dose may be increased as high as 10 mg/kg/dose once daily for life-threatening infection (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IV: 3 to 5 mg/kg/dose once daily until clinical improvement, then change to fluconazole or itraconazole (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Histoplasmosis, disseminated disease (moderately severe to severe): </b>HIV-exposed/-positive: Adolescents: IV: 3 mg/kg/dose once daily for at least 2 week induction, followed by oral itraconazole (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b><i>Aspergillosis</i>, invasive, treatment:</b> IV: Usual dosage range: 3 to 4 mg/kg/day. <b>Note:</b> 6 mg/kg/day has been used for treatment of life-threatening aspergillosis in immunocompromised patients (Bowden 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: There are no dosage adjustments provided in manufacturer's labeling; however, no pharmacokinetic changes were noted in patients with mild to moderate impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: There are no dosage adjustments provided in manufacturer's labeling; however, no pharmacokinetic changes were noted in patients with mild to moderate impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134738\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amphotec: 50 mg (1 ea [DSC]); 100 mg (1 ea [DSC]) [contains edetate disodium, hydrochloric acid, lactose, sodium cholesteryl sulfate, tromethamine]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134723\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50617169\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Amphotec has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998159\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: Do not filter or use an inline filter for administration. Flush line with D5W prior to and following infusion.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Initially infuse diluted solution at 1 mg/kg/hour. Rate of infusion may be increased with subsequent doses as patient tolerance allows (minimum infusion time: 2 hours). If utilizing test dose as recommended by the manufacturer&rsquo;s labeling, infuse over 15 to 30 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2508621\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). After reconstitution, the solution should be refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) and used within 24 hours. Concentrations of 0.1-2 mg/mL in D<sub>5</sub>W are stable for 24 hours at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998130\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of invasive aspergillosis in patients who have failed amphotericin B deoxycholate treatment, or who have renal impairment or unacceptable toxicity which precludes treatment with amphotericin B deoxycholate in effective doses (FDA approved in pediatric patients [age not specified] and adults); has also been used for treatment of candidiasis, coccidiodomycosis, and histoplasmosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134780\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lipid-based amphotericin formulations (Amphotec) may be confused with conventional formulations (Amphocin, Fungizone) </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134777\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Amphotericin B colloidal dispersion has an improved therapeutic index compared to conventional amphotericin B, and has been used safely in patients with amphotericin B-related nephrotoxicity; however, continued decline of renal function has occurred in some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Cardiovascular: Chest pain, facial edema, hypertension, hypotension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Abnormality in thinking, chills, drowsiness, headache, insomnia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaphoresis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hyperglycemia, hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, diarrhea, enlargement of abdomen, hematemesis, nausea, stomatitis, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, hemorrhage, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal hepatic function tests, hyperbilirubinemia, increased serum alkaline phosphatase, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain, muscle rigidity, tremor </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea, epistaxis, hypoxia, increased cough, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Rare but important or life-threatening: Acidosis, atrial arrhythmia, cardiac arrest, cardiac failure, gastrointestinal hemorrhage, hepatic failure, injection site reaction, oliguria, pain at injection site, pleural effusion, renal failure, seizure, syncope, ventricular arrhythmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134744\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amphotericin B or any component of the formulation (unless the benefits outweigh the possible risk to the patient)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134727\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs, the infusion should be immediately discontinued; the patient should not receive further infusions. During the initial dosing, the drug should be administered under close clinical observation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Acute infusion reactions, sometimes severe, may occur 1-3 hours after starting infusion. These reactions are usually more common with the first few doses and generally diminish with subsequent doses. Pretreatment with antihistamines/corticosteroids and/or decreasing the rate of infusion can be used to manage reactions. Avoid rapid infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, amphotericin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: moderate/major) (AHA [Page 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27120261\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">In a multicenter study of pediatric patients (&lt;16 years of age), amphotericin B cholestyrel sulfate complex (ABCD) use had a significantly lower incidence of renal toxicity (12%; 3/25 patients) than amphotericin B deoxycholate (52%; 11/21 patients).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298747\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134732\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=100046&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Stibogluconate: Amphotericin B may enhance the cardiotoxic effect of Sodium Stibogluconate. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134734\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13314096\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women; refer to current guidelines (IDSA [Pappas 2016]; King 1998; Pilmis 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998162\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests, electrolytes, BUN, Cr, vital signs, CBC, I &amp; O, prothrombin time, signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134726\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages (Lyman, 1992).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134743\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Total volume increases with higher doses, reflects increasing uptake by tissues (with 4 mg/kg/day = 4 L/kg); predominantly distributed in the liver; concentrations in kidneys and other tissues are lower than observed with conventional amphotericin B (Walsh 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~28 hours; prolonged with higher doses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998167\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">The lipid portion of amphotericin B cholesteryl sulfate complex formulation does not contain phospholipids; for patients receiving parenteral nutrition, adjustment to the amount of lipids should not be needed (Sacks 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322987\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Amphotec Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $93.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $160.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134748\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amphocil (AU, DK, ES, GR, HK, HN, HU, IT, MX, MY, NL, PL, SI, TH, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amphotec (amphotericin b cholesteryl sulfate complex) [prescribing information]. Bedford, OH: Ben Venue Laboratories, Inc; July 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: A scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin b colloidal dispersion versus amphotericin b for treatment of invasive aspergillosis in immunocompromised patients. <i>Clin Infect Dis</i> 2002; 35:359-366.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from  the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. November 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed December 5, 2016<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/11705428/pubmed\" target=\"_blank\" id=\"11705428\">11705428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King CT, Rogers PD, Cleary JD, Chapman SW. Antifungal therapy during pregnancy. <i>Clin Infect Dis</i>. 1998;27(5):1151-1160.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/9827262 /pubmed\" target=\"_blank\" id=\"9827262 \">9827262 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. <i>J Antimicrob Chemother</i>. 2003;52(4):663-667.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/12972450 /pubmed\" target=\"_blank\" id=\"12972450 \">12972450 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman CA, Walsh TJ. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeuticapplications. <i>Drugs</i>. 1992;44(1):9-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/1379913/pubmed\" target=\"_blank\" id=\"1379913\">1379913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mactal-Haaf C, Hoffman M, Kuchta A. Use of anti-infective agents during lactation, part 3: antivirals, antifungals, and urinary antiseptics. <i>J Hum Lact</i>. 2001;17(2):160-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/1379913/pubmed\" target=\"_blank\" id=\"1379913\">1379913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paterson DL, David K, Mrsic M, et al. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.<i> J Antimicrob Chemother</i>. 2008;62(6):1392-1400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/18812423 /pubmed\" target=\"_blank\" id=\"18812423 \">18812423 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sacks GS, Cleary JD. Nutritional impact of lipid-associated amphotericin B formulations.<i> Ann Pharmacother</i>. 1997;31(1):121-122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/8997484 /pubmed\" target=\"_blank\" id=\"8997484 \">8997484 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandler ES, Mustafa MM, Tkaczewski I, et al. Use of amphotericin B colloidal dispersion in children. <i>J Pediatr Hematol Oncol</i>. 2000;22(3):242-246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/10864055 /pubmed\" target=\"_blank\" id=\"10864055 \">10864055 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slain D. Lipid-based amphotericin B for the treatment of fungal infections. <i>Pharmacotherapy</i>. 1999;19(3):306-323.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice? <i>Curr Opin Infect Dis</i>. 2011;24(2):163-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/21301335 /pubmed\" target=\"_blank\" id=\"21301335 \">21301335 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2008;46(3):327-360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information/abstract-text/18177225 /pubmed\" target=\"_blank\" id=\"18177225 \">18177225 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 100046 Version 38.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F134753\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F998129\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F45360845\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F998155\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F134738\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F134723\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50617169\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F998159\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2508621\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F998130\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134780\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134777\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134744\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134727\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F27120261\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298747\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134732\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134734\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13314096\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F998162\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134726\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F134743\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F998167\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322987\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F134748\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/100046|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-drug-information\" class=\"drug drug_general\">Amphotericin B cholesteryl sulfate complex (United States: not available): Drug information</a></li><li><a href=\"topic.htm?path=amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Amphotericin B cholesteryl sulfate complex (United States: not available): Patient drug information</a></li></ul></div></div>","javascript":null}